Analysts Expect AxoGen, Inc. (NASDAQ:AXGN) Will Announce Earnings of -$0.08 Per Share
Brokerages predict that AxoGen, Inc. (NASDAQ:AXGN) will announce earnings of ($0.08) per share for the current quarter, Zacks reports. Three analysts have issued estimates for AxoGen’s earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.06). AxoGen also posted earnings per share of ($0.08) in the same quarter last year. The company is scheduled to report its next quarterly earnings results on Wednesday, November 1st.
On average, analysts expect that AxoGen will report full-year earnings of ($0.33) per share for the current year, with EPS estimates ranging from ($0.42) to ($0.29). For the next fiscal year, analysts forecast that the business will report earnings of ($0.09) per share, with EPS estimates ranging from ($0.22) to $0.02. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow AxoGen.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The firm had revenue of $15.20 million for the quarter, compared to the consensus estimate of $14.40 million. During the same quarter last year, the business posted ($0.09) earnings per share. The firm’s revenue was up 46.2% compared to the same quarter last year.
A number of equities research analysts recently issued reports on the company. BidaskClub lowered AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Cantor Fitzgerald assumed coverage on AxoGen in a research note on Thursday, June 29th. They issued an “overweight” rating and a $18.00 target price on the stock. Leerink Swann assumed coverage on AxoGen in a research note on Monday, July 31st. They issued an “outperform” rating and a $22.00 target price on the stock. ValuEngine raised AxoGen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Wedbush reissued an “outperform” rating and set a $14.00 price target (down previously from $17.00) on shares of AxoGen in a research note on Friday, May 19th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. AxoGen currently has a consensus rating of “Buy” and an average target price of $15.90.
AxoGen (NASDAQ AXGN) opened at 14.70 on Thursday. The stock’s market cap is $488.63 million. The company’s 50-day moving average price is $15.88 and its 200-day moving average price is $12.73. AxoGen has a 12 month low of $7.65 and a 12 month high of $17.25.
WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/10/analysts-expect-axogen-inc-nasdaqaxgn-will-announce-earnings-of-0-08-per-share.html.
Several hedge funds and other institutional investors have recently modified their holdings of AXGN. American International Group Inc. raised its position in shares of AxoGen by 7.7% in the first quarter. American International Group Inc. now owns 14,941 shares of the medical equipment provider’s stock worth $156,000 after buying an additional 1,068 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of AxoGen during the first quarter worth $150,000. Millrace Asset Group Inc. raised its position in shares of AxoGen by 4.5% in the first quarter. Millrace Asset Group Inc. now owns 230,000 shares of the medical equipment provider’s stock worth $2,404,000 after buying an additional 10,000 shares in the last quarter. Trexquant Investment LP acquired a new position in shares of AxoGen during the first quarter worth $183,000. Finally, Campbell & CO Investment Adviser LLC raised its position in shares of AxoGen by 3.2% in the first quarter. Campbell & CO Investment Adviser LLC now owns 11,055 shares of the medical equipment provider’s stock worth $116,000 after buying an additional 341 shares in the last quarter. 64.58% of the stock is currently owned by institutional investors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.